Table 1 Clinical characteristics and post-CAR T outcomes
Patient Number | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
Age (years) | 51 | 51 | 53 | 47 | 56 | 63 |
Sex | Male | Male | Female | Female | Female | Male |
Diagnosis/subtype | TFL | DLBCL/GCB | DLBCL/non-GCB | HGBL (Triple hit) | DLBCL/non-GCB | DLBCL/non-GCB |
ECOG PS1 | 1 | 3 | 1 | 3 | 3 | 1 |
Prior therapy | R-CHOP; 2-HyperCVAD-A | R-CHOP; R-BEAM + ASCT | R-CHOP; R-GDP; R2-COP + mitoxantrone; BEAM + ASCT | CHOP; R- EPOCH; R-DA-EPOCH; DHAP | R- EPOCH; R-GeMox; ICE2 R-COP2; Ibrutinib2 | R-CHOP; R-GDP; R2-MINE; R-DHAP |
Disease Stage1 | 4 | 3 | 4 | 4 | 4 | 3 |
B Symptom1 | A | A | B | A | A | A |
PD-L11 | 20% | 25% | Negative | Negative | Negative | Negative |
Ki-671 | 80% | 50% | 80% | 100% | 40% | 80% |
IPI Score1 | 2 | 3 | 3 | 3 | 4 | 2 |
First CAR-T | ||||||
Costimulatory domain | 4-1BB | 4-1BB | CD28 | CD28 | 4-1BB | 4-1BB |
Dose (106/kg) | 0.50 | 1.00 | 0.88 | 1.78 | 4.00 | 2.00 |
Response | PR | PD | PD | PD | PR | CR |
DOR (Month) | 4 | NA | NA | NA | 3 | 30 |
Second CAR-T | ||||||
ECOG PS | 2 | 4 | 1 | 4 | 3 | 1 |
Dose (106/kg) | 0.32 | 0.63 | 0.50 | 2.90 | 4.00 | 2.00 |
Response | PD | ED | CR | ED | CR | CR |
DOR (Month) | NA | NA | 25 | NA | 8 | 14 |
PBMC Source | Leukapheresis | Cryopreservation | Cryopreservation | Cryopreservation | Leukapheresis | Leukapheresis |
Time for CAR-T culture (Day) | 15 | 14 | 14 | 13 | 14 | 12 |
Naïve T (%) | 1.89 | 29.85 | 25.35 | 51.9 | 31.25 | 28.64 |
TCM T (%) | 60.48 | 26.84 | 40.49 | 42.89 | 47.97 | 13.66 |
TEM T (%) | 1.14 | 21.35 | 23.26 | 3.81 | 13.61 | 13.16 |
TEMRA T (%) | 36.49 | 21.96 | 10.90 | 1.40 | 7.17 | 44.55 |